Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
-
Authors :
ZHOU FANGJIAN, Head of UrologyDepartment,Sun Yat-sen University Cancer center
-
Source:
The Efficacy and Safety of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy:An Open,
تفاصيل العنوان
-
Source:
Hepatic Arterial Infusion Chemotherapy Combined with PD-1 Inhibitor in Treating Potentially Resectable Locally Advanced Hepatocellular Carcinoma: a Prospective, Phase II Clinical StudyLyu N,
تفاصيل العنوان
-
Authors :
Hai-Qiang Mai,MD,PhD, MD, PhD
-
Source:
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
تفاصيل العنوان
-
Source:
A Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Tislelizumab + Chemotherapy Followed by Adjuvant Tislelizumab for the Treatment of Patients With Locoregionally Advanced
تفاصيل العنوان
-
Authors :
Hai-Qiang Mai,MD,PhD, Director of the Department of Nasopharyngeal Carcinoma
-
Source:
Efficacy and Safety of of GP Chemotherapy Combined With Tislelizumab Neoadjuvant Therapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: a Single-arm, Phase 2 TrialHsu C, Lee
تفاصيل العنوان
-
Authors :
Xin Huang, Professor
-
Source:
Toripalimab, a Anti-PD-1 Antibody, and Histone Deacetylase Inhibitor Chidamide in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer, a Multicenter, Open-label, Single-arm, Phase Ib/II
تفاصيل العنوان
-
Source:
A Phase Ⅱ ,Open-label ,Single Institution Study to Investigate the Efficacy and Safety of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma
تفاصيل العنوان
-
Source:
A Phase Ⅱ ,Open-label ,Single Institution Study to Investigate the Efficacy and Safety of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Locally , Resectable
تفاصيل العنوان
-
Authors :
ZHOU FANGJIAN, Director Of Urology, Sun Yat-sen University Cancer Center
-
Source:
A Study of Anti-PD-1( Pembrolizumab) Combinations of D-CIK (Cytokine-induced Killer Cells Are Stimulated Using Mature Dendritic Cells) Immunotherapy and Axitinib in Advanced Ranal CarcinomaRini
تفاصيل العنوان
